Reply To: World’s Failure

2scents -“In fact, you first stated that it was published in medscape, but it really was in a sham website.”

The only one that can be called a Sham is You and anybody else who Blindly follows the Corrupt Government!

“Which essentially means you are taking them at face value.”

I take everything at face value, until I find differently.
Just like I used to take American Hatzolahs at face value, but I don’t anymore.

“Just to demonstrate why it would be important to actually check all these “studies”, they are smaller observations, at best. And some are ridiculous.
The Quercitin “study”, takes 100 subjects, some that took the regiment, others that did not, and after 5 weeks, 6 from the group that took it reported having flu-like symptoms, vs 12 from the control group.”

This shows once a Liar – Always a Liar.
Here’s the Real study that – that Website was based on:
“6/8 Early treatment study
Di Pierro et al., International Journal of General Medicine, doi:10.2147/IJGM.S318720 (Peer Reviewed)
Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study
Source PDF Share Tweet
RCT 152 outpatients in Pakistan, 76 treated with quercetin phytosome, showing lower mortality, ICU admission, and hospitalization with treatment.
Di Pierro et al., 6/8/2021, Randomized Controlled Trial, Pakistan, South Asia, peer-reviewed, 19 authors.
risk of death, 85.7% lower, RR 0.14, p = 0.25, treatment 0 of 76 (0.0%), control 3 of 76 (3.9%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 94.1% lower, RR 0.06, p = 0.006, treatment 0 of 76 (0.0%), control 8 of 76 (10.5%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 68.2% lower, RR 0.32, p = 0.003, treatment 7 of 76 (9.2%), control 22 of 76 (28.9%).”

“RCT 42 outpatients in Pakistan, 21 treated with quercetin phytosome, showing faster viral clearance and lower symptom severity with treatment.
Di Pierro et al., 6/24/2021, Randomized Controlled Trial, Pakistan, South Asia, peer-reviewed, 12 authors.
risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of ICU admission, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 66.7% lower, RR 0.33, p = 1.00”